protein

Recombinant Human ELFN2 Protein, CF

9329-EF-050

50 ug

524 USD

9329-EF-050

Recombinant Human ELFN2 Protein, CF

50 ug

The Recombinant Human ELFN2 Protein, CF from R&D Systems is derived from HEK293. The Recombinant Human ELFN2 Protein, CF has been validated for the following applications: Bioactivity.

ELFN2

Proteins and Enzymes

Lyophilized from a 0.2 ╡m filtered solution in PBS.

Unconjugated

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

Human

71-94 kDa, non-reducing conditions

43 kDa

Measured by its ability to inhibit neurite outgrowth of E16-E18 rat embryonic cortical neurons on a Laminin alpha 4 coated plate. Able to significantly inhibit neurite outgrowth when immobilized as a 3 ╡L droplet containing 300 ng of protein.

<0.10 EU per 1 ╡g of the protein by the LAL method.

Q5R3F8

Bioactivity

Human embryonic kidney cell, HEK293-derived human ELFN2 protein Asp23-Tyr397, with a C-terminal 6-His tag

HEK293

524 USD

dJ63G5.3, dJ63G5.3 (putative Leucine rich protein), ELFN2, extracellular leucine-rich repeat and fibronectin type III containing 2, extracellular leucine-rich repeat and fibronectin type III domain containing 2, extracellular leucine-rich repeat and fibronectin type III domain-containing protein 2, KIAA1904, leucine rich repeat containing 62, leucine-rich repeat and fibronectin type-III domain-containing protein 6, leucine-rich repeat-containing protein 62, LRRC62, PPP1R29, protein phosphatase 1, regulatory subunit 29

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.